Tuberculosis

Dutch biotech, Aeras Foundation announce progress in TB vaccine program

Published in TB and Outbreaks Week, October 11th, 2005

Dutch biotechnology company Crucell, NV, (CRXL) and Aeras Global TB Vaccine Foundation announced the initiation of a series of clinical studies for their AdVac-based tuberculosis (TB) vaccine.

The studies, which follow promising results for the vaccine obtained in animal studies, are scheduled to start in Europe, the U.S., and Africa in the second quarter of 2006.

The announcement was made by Crucell Chief Scientific Officer Dr. Jaap Goudsmit, at a congress held in Berlin, Germany, called "New Approaches to Vaccine Development - From the Bench to the Field."

Goudsmit's lecture, entitled "Children's Vaccines Against HIV, Malaria...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2005-10-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry